Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Invesco Galaxy Bitcoin ETF (BTCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Invesco Galaxy Bitcoin ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Invesco Galaxy Bitcoin ETF trades at $61.83. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | BTCO | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Crypto-linked |
52-Week High | $28.06 | $125.14 |
52-Week Low | $20.06 | $58.40 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BTCO is trading at $63.38, up 3.63% today, but technical indicators signal a bearish trend with moving averages showing significant selling pressure. The stock faces resistance at $64 and support at $58. Recent news highlights investor caution toward cryptocurrency-related assets, though BTCO's specific financial metrics remain undisclosed in available data.
The outlook for BTCO is cautious due to bearish technical signals and negative sentiment around crypto-exposed stocks. Key risks include market volatility and reliance on cryptocurrency trends. Investors should await clearer fundamental data to assess valuation and growth prospects amid current headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Invesco Galaxy Bitcoin ETF
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →
